These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 9292151)

  • 1. "Aggrecanase" activity is implicated in tumour necrosis factor alpha mediated cartilage aggrecan breakdown but is not detected by an in vitro assay.
    Buttle DJ; Fowles A; Ilic MZ; Handley CJ
    Mol Pathol; 1997 Jun; 50(3):153-9. PubMed ID: 9292151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine-induced cartilage proteoglycan degradation is mediated by aggrecanase.
    Arner EC; Hughes CE; Decicco CP; Caterson B; Tortorella MD
    Osteoarthritis Cartilage; 1998 May; 6(3):214-28. PubMed ID: 9682788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies that specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro.
    Hughes CE; Caterson B; Fosang AJ; Roughley PJ; Mort JS
    Biochem J; 1995 Feb; 305 ( Pt 3)(Pt 3):799-804. PubMed ID: 7531436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro.
    Little CB; Flannery CR; Hughes CE; Mort JS; Roughley PJ; Dent C; Caterson B
    Biochem J; 1999 Nov; 344 Pt 1(Pt 1):61-8. PubMed ID: 10548534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cleavage of native cartilage aggrecan by neutrophil collagenase (MMP-8) is distinct from endogenous cleavage by aggrecanase.
    Arner EC; Decicco CP; Cherney R; Tortorella MD
    J Biol Chem; 1997 Apr; 272(14):9294-9. PubMed ID: 9083065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine.
    Sandy JD; Gamett D; Thompson V; Verscharen C
    Biochem J; 1998 Oct; 335 ( Pt 1)(Pt 1):59-66. PubMed ID: 9742213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interglobular domain of cartilage aggrecan is cleaved by hemorrhagic metalloproteinase HT-d (atrolysin C) at the matrix metalloproteinase and aggrecanase sites.
    Tortorella MD; Pratta MA; Fox JW; Arner EC
    J Biol Chem; 1998 Mar; 273(10):5846-50. PubMed ID: 9488721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation.
    Tortorella MD; Malfait AM; Deccico C; Arner E
    Osteoarthritis Cartilage; 2001 Aug; 9(6):539-52. PubMed ID: 11520168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly sulfated glycosaminoglycans inhibit aggrecanase degradation of aggrecan by bovine articular cartilage explant cultures.
    Munteanu SE; Ilic MZ; Handley CJ
    Matrix Biol; 2002 Aug; 21(5):429-40. PubMed ID: 12225808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coincubation of bovine synovial or capsular tissue with cartilage generates a soluble "Aggrecanase" activity.
    Vankemmelbeke MN; Ilic MZ; Handley CJ; Knight CG; Buttle DJ
    Biochem Biophys Res Commun; 1999 Feb; 255(3):686-91. PubMed ID: 10049771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of bovine nasal cartilage degradation by selective matrix metalloproteinase inhibitors.
    Bottomley KM; Borkakoti N; Bradshaw D; Brown PA; Broadhurst MJ; Budd JM; Elliott L; Eyers P; Hallam TJ; Handa BK; Hill CH; James M; Lahm HW; Lawton G; Merritt JE; Nixon JS; Röthlisberger U; Whittle A; Johnson WH
    Biochem J; 1997 Apr; 323 ( Pt 2)(Pt 2):483-8. PubMed ID: 9163342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human aggrecan G1-G2 exhibits native binding properties and substrate specificity for matrix metalloproteinases and aggrecanase.
    Mercuri FA; Doege KJ; Arner EC; Pratta MA; Last K; Fosang AJ
    J Biol Chem; 1999 Nov; 274(45):32387-95. PubMed ID: 10542281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bovine joint capsule and fibroblasts derived from joint capsule express aggrecanase activity.
    Ilic MZ; Vankemmelbeke MN; Holen I; Buttle DJ; Clem Robinson H; Handley CJ
    Matrix Biol; 2000 Jul; 19(3):257-65. PubMed ID: 10936450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human osteoarthritis synovial fluid and joint cartilage contain both aggrecanase- and matrix metalloproteinase-generated aggrecan fragments.
    Struglics A; Larsson S; Pratta MA; Kumar S; Lark MW; Lohmander LS
    Osteoarthritis Cartilage; 2006 Feb; 14(2):101-13. PubMed ID: 16188468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance of small leucine-rich repeat proteoglycans to proteolytic degradation during interleukin-1-stimulated cartilage catabolism.
    Sztrolovics R; White RJ; Poole AR; Mort JS; Roughley PJ
    Biochem J; 1999 May; 339 ( Pt 3)(Pt 3):571-7. PubMed ID: 10215595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium pentosan polysulfate inhibits the catabolism of aggrecan in articular cartilage explant cultures.
    Munteanu SE; Ilic MZ; Handley CJ
    Arthritis Rheum; 2000 Oct; 43(10):2211-8. PubMed ID: 11037880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a novel clinical biomarker assay to detect and quantify aggrecanase-generated aggrecan fragments in human synovial fluid, serum and urine.
    Swearingen CA; Carpenter JW; Siegel R; Brittain IJ; Dotzlaf J; Durham TB; Toth JL; Laska DA; Marimuthu J; Liu C; Brown DP; Carter QL; Wiley MR; Duffin KL; Mitchell PG; Thirunavukkarasu K
    Osteoarthritis Cartilage; 2010 Sep; 18(9):1150-8. PubMed ID: 20633682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporin A inhibition of aggrecanase-mediated proteoglycan catabolism in articular cartilage.
    Little CB; Hughes CE; Curtis CL; Jones SA; Caterson B; Flannery CR
    Arthritis Rheum; 2002 Jan; 46(1):124-9. PubMed ID: 11817583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mechanism of aggrecan release from cartilage differs with tissue origin and the agent used to stimulate catabolism.
    Sztrolovics R; White RJ; Roughley PJ; Mort JS
    Biochem J; 2002 Mar; 362(Pt 2):465-72. PubMed ID: 11853556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A short-term pharmacodynamic model for monitoring aggrecanase activity: injection of monosodium iodoacetate (MIA) in rats and assessment of aggrecan neoepitope release in synovial fluid using novel ELISAs.
    Swearingen CA; Chambers MG; Lin C; Marimuthu J; Rito CJ; Carter QL; Dotzlaf J; Liu C; Chandrasekhar S; Duffin KL; Mitchell PG; Durham TB; Wiley MR; Thirunavukkarasu K
    Osteoarthritis Cartilage; 2010 Sep; 18(9):1159-66. PubMed ID: 20633676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.